Patents by Inventor Suoming Zhang

Suoming Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11008345
    Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: May 18, 2021
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Vincent S. Hernandez, Charles Ding, Jacob J. Plattner, Michael Richard Kevin Alley, Fernando Rock, Suoming Zhang, Eric Easom, Xianfeng Li, Ding Zhou
  • Publication number: 20210096682
    Abstract: A system may include a display driven using display driving circuitry to present an image via pixels. The display driving circuitry may include a sensor core compatible with one or more strain sensing circuits. The same sensor core may be used by a control system of the display to sense a stress applied to a strained region of a display using a current divider sensing circuit and/or a Wheatstone bridge sensing circuit.
    Type: Application
    Filed: August 26, 2020
    Publication date: April 1, 2021
    Inventors: Zhen Zhang, Baris Cagdaser, Chieh-Chien Lin, Derek Keith Shaeffer, Jesse Aaron Richmond, Suoming Zhang
  • Publication number: 20190345173
    Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
    Type: Application
    Filed: July 30, 2019
    Publication date: November 14, 2019
    Inventors: VINCENT S. HERNANDEZ, CHARLES DING, JACOB J. PLATTNER, MICHAEL RICHARD KEVIN ALLEY, FERNANDO ROCK, SUOMING ZHANG, ERIC EASOM, XIANFENG LI, DING ZHOU
  • Publication number: 20190330201
    Abstract: The disclosure discloses an aryl hydrocarbon receptor modulators of formula (I), and pharmaceutically acceptable salts, R? is H, CN, CH2(OH)R0, CmH2m+1, CnH2n-1, CnH2n-3, two Ra is independently H, or two Ra together form ?O or ?N—W3—R1; A is a C6 to C10 aromatic ring, or a C2 to C10 heteroaromatic ring containing 1 to 5 heteroatom from N, O and S, or 4 to 7 membered non-aromatic heterocyclic ring containing 1 to 3 heteroatom from N, O and S and C?N, which are with no substituent or substituted by 1 or 3 R; Q is R, or a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring containing 1 to 5 heteroatom selected from N, O and S, which are with no substituent or substituted by 1 or 3 R; R is Rc connected with C or RN connected with N.
    Type: Application
    Filed: December 22, 2017
    Publication date: October 31, 2019
    Inventors: Luqing YANG, Guodong LI, Suoming ZHANG
  • Publication number: 20190307731
    Abstract: Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein R? is H, CN, CH2(OH)R0, CmH2m+1, CnH2n-1, CnH2n-3, two Ra are independently H or two Ra together form ?O or ?N—W3—R1; A is a C6 to C10 aromatic ring unsubstituted or substituted with 1 to 3 R, or a C2-C10 heteroaromatic ring interrupted by 1 to 5 heteroatoms selected from N, O, and S or a 4 to 7 membered nonaromatic heterocyclic ring containing C?N and interrupted by 1 to 3 heteroatoms selected from N, O, and S, with either one unsubstituted or substituted with 1 to 3 R; Q is R, or is a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring unsubstituted or substituted with 1 to 3 R and interrupted by 1 to 5 heteroatoms selected from N, O, and S; and R is Rc which is C-attached or RN which is N-attached.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 10, 2019
    Applicant: Ariagen, Inc.
    Inventors: Luqing YANG, Guodong LI, Suoming ZHANG
  • Publication number: 20190284149
    Abstract: Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein R? is H, CN, CH2(OH)R0, CmH2m+1, CnH2n?1, CnH2n?3, two Ra are independently H or two Ra together form =0 or ?N—W3—R1; A is a C6 to C10 aromatic ring unsubstituted or substituted with 1 to 3 R, or a C2-C10 heteroaromatic ring interrupted by 1 to 5 heteroatoms selected from N, 0, and S or a 4 to 7 membered nonaromatic heterocyclic ring containing C?N and interrupted by 1 to 3 heteroatoms selected from N, 0, and S, with either one unsubstituted or substituted with 1 to 3 R; Q is R, or is a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring unsubstituted or substituted with 1 to 3 R and interrupted by 1 to 5 heteroatoms selected from N, 0, and S; and R is RC which is C-attached or RN which is N-attached.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 19, 2019
    Applicant: ARIAGEN, INC.
    Inventors: Jiasheng Song, Suoming Zhang, Guodong Li, Luqing Yang
  • Publication number: 20190084948
    Abstract: Methods of synthesizing 2?(1?H-indole-3?-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and structural analogs thereof. The methods include condensation reactions or condensation and oxidation reactions to form the thiazoline or thiazole moiety of ITE or its structural analogs.
    Type: Application
    Filed: August 16, 2018
    Publication date: March 21, 2019
    Applicant: Ariagen, Inc.
    Inventors: Jiasheng Song, Suoming Zhang, Guodong Li, Luqing Yang
  • Patent number: 10081610
    Abstract: Methods of synthesizing 2-(1?H-indole-3?-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and structural analogs thereof. The methods include condensation reactions or condensation and oxidation reactions to form the thiazoline or thiazole moiety of ITE or its structural analogs.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: September 25, 2018
    Assignee: ARIAGEN, INC.
    Inventors: Jiasheng Song, Suoming Zhang, Guodong Li, Luquing Yang
  • Publication number: 20170355719
    Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
    Type: Application
    Filed: August 24, 2017
    Publication date: December 14, 2017
    Inventors: Vincent S. Hernandez, Charles Ding, Jacob J. Plattner, Michael Richard Kevin Alley, Fernando Rock, Suoming Zhang, Eric Easom, Xianfeng Li, Ding Zhou
  • Publication number: 20170291881
    Abstract: Methods of synthesizing 2-(1?H-indole-3?-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and structural analogs thereof. The methods include condensation reactions or condensation and oxidation reactions to form the thiazoline or thiazole moiety of ITE or its structural analogs.
    Type: Application
    Filed: September 10, 2015
    Publication date: October 12, 2017
    Applicant: AhR Pharmaceuticals, Inc.
    Inventors: Jiasheng Song, Suoming Zhang, Guodong Li, Luqing Yang
  • Patent number: 9751898
    Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: September 5, 2017
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Vincent S. Hernandez, Charles Ding, Jacob J. Plattner, Michael Richard Kevin Alley, Fernando Rock, Suoming Zhang, Eric Easom, Xianfeng Li, Ding Zhou
  • Patent number: 9610317
    Abstract: The invention provides pharmaceutical compositions comprising a compound of formula or a pharmaceutically acceptable salt or hydrate thereof. The compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication, and the invention provides methods for treating Hepatitis C infections.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: April 4, 2017
    Assignee: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Avinash Phadke, Xiangzhu Wang, Suoming Zhang, Atul Agarwal
  • Publication number: 20160082069
    Abstract: The invention provides pharmaceutical compositions comprising a compound of formula or a pharmaceutically acceptable salt or hydrate thereof. The compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication, and the invention provides methods for treating Hepatitis C infections.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 24, 2016
    Inventors: Avinash Phadke, Xiangzhu Wang, Suoming Zhang, Atul Agarwal
  • Patent number: 9233136
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: January 12, 2016
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Avinash Phadke, Xiangzhu Wang, Suoming Zhang, Atul Agarwal
  • Patent number: 8969373
    Abstract: A compound of general formula (I); A is O, S, CH, NH or NR?, when O links with Z3, Z1 is N or CRZ1, Z2 is CRZ2, when Z1 links with O, Z2 is CH, Z3 is C—Ar; Ra, Rb, Rc and Rd independently is H, OH, halogen or —Y1—Rm; A1 is NH or CH2; R1? is alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl; A2 is N, O or linking bond; R1 is hydrogen, or, R1 linking covalently with R3 forms C5-C9 saturated or unsaturated hydrocarbon chain substituted by O or N; R3 is alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted by cycloalkyl etc; R4 is alkoxy-CO, alkyl-NHCO, (alkyl)2NCO, or formyl substituted by aryl, cycloalkyl, heterocycloalkyl.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: March 3, 2015
    Assignee: Shanghai Tangrun Pharmaceuticals Co., Ltd.
    Inventor: Suoming Zhang
  • Publication number: 20140328796
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 6, 2014
    Inventors: Avinash Phadke, Xiangzhu Wang, Suoming Zhang, Atul Agarwal
  • Publication number: 20140315860
    Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 23, 2014
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Vincent S. HERNANDEZ, Charles Ding, Jacob J. Plattner, Michael Richard Kevin Alley, Fernando Rock, Suoming Zhang, Eric Easom, Xianfeng Li, Ding Zhou
  • Publication number: 20140206604
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Formula I and the pharmaceutically salts thereof. The variables are defined herein. Certain compounds of Formula I are useful as antiviral agents. 4-amino-4-oxobutanoyl peptide cyclic analogues as disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide cyclic analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptide cyclic analogue as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptide cyclic analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in patients.
    Type: Application
    Filed: March 24, 2014
    Publication date: July 24, 2014
    Applicant: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Avinash Phadke, Xiangzhu Wang, Godwin Pais, Akihiro Hashimoto, Venkat Gadhachanda, Dawei Chen, Atul Agarwal, Suoming Zhang, Cuixian Liu, Shouming Li, Milind Deshpande
  • Patent number: 8785378
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: July 22, 2014
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Avinash Phadke, Xiangzhu Wang, Suoming Zhang, Atul Agarwal
  • Publication number: 20140163219
    Abstract: A compound of general formula (I); A is O, S, CH, NH or NR?, when O links with Z3, Z1 is N or CRZ1, Z2 is CRZ2, when Z1 links with O, Z2 is CH, Z3 is C—Ar; Ra, Rb, Rc and Rd independently is H, OH, halogen or —Y1—Rm; A1 is NH or CH2; R1? is alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl; A2 is N, O or linking bond; R1 is hydrogen, or, R1 linking covalently with R3 forms C5-C9 saturated or unsaturated hydrocarbon chain substituted by O or N; R3 is alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted by cycloalkyl etc; R4 is alkoxy-CO, alkyl-NHCO, (alkyl)2NCO, or formyl substituted by aryl, cycloalkyl, heterocycloalkyl.
    Type: Application
    Filed: July 23, 2012
    Publication date: June 12, 2014
    Applicant: Shanghai Tangrun Pharmaceuticals, Co., Ltd.
    Inventor: Suoming Zhang